369 results about "Osteocyte" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

The invention provides modified milk powder capable of promoting bone health as well as a preparation method and application of the modified milk powder. The total protein content of the modified milk powder is 17-35 g / 100 g, the fat content of the modified milk powder is 1-32 g / 100 g, and the calcium content of the modified milk powder is 0.8-2.1 g / 100 g. Moreover, the modified milk powder contains bovine coloctrum and lactoferrin, the mass ratio of the bovine coloctrum to the lactoferrin is (5-100): 1 on the basis of the dry matter content, and the content of the lactoferrin in the modified milk powder is 2-400 mg / 100 g. The bovine colostrum and the lactoferrin are combined for preparing the milk powder, have a synergistic effect on promoting osteoblasts and inhibiting osteoclast proliferation, and are beneficial to bone health.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention discloses an eggshell membrane peptide for enhancing bone mineral density as well as a preparation method and application thereof, belongs to the technical field of egg by-product processing, and particularly relates to a preparation method of the eggshell membrane peptide for enhancing bone mineral density, which comprises the following steps: carrying out vacuum freeze drying and crushing on an eggshell membrane to obtain eggshell membrane powder; mixing the eggshell membrane powder with deionized water to obtain an eggshell membrane solution; adding keratinase, performing enzymolysis, and taking supernate; adding collagenase, carrying out enzymolysis, and centrifuging to take supernate, so as to obtain primary enzymatic hydrolysate; adding alkaline phosphatase, performing enzymolysis and centrifugation, and taking supernate to obtain enzymatic hydrolysate; and performing ultrafiltration and drying to obtain the eggshell membrane peptide. According to the eggshell membrane peptide for enhancing the bone mineral density, keratin cross-linking is destroyed through enzymolysis of keratinase, active peptide capable of stimulating osteoblast proliferation is released through enzymolysis of collagenase, phosphopeptide calcium binding sites are further activated through enzymolysis of alkaline phosphatase, calcium salt deposition is promoted, and the eggshell membrane peptide for enhancing the bone mineral density is provided.

The invention relates to the technical field of recombinant proteins, and relates to a recombinant XII type collagen as well as a preparation method and application thereof. The recombinant XII type collagen is formed by connecting 5-30 repetitive units in series, and the amino acid sequence of each repetitive unit is as shown in SEQ ID NO: 1. The nucleic acid molecule is used for coding the recombinant XII type collagen; a vector comprises the nucleic acid molecule. According to the invention, a nucleotide sequence for coding the amino acid sequence is inserted into a vector to obtain a recombinant plasmid vector, then the recombinant plasmid vector is introduced into a host cell for culture, and then separation and purification are carried out to obtain the recombinant XII type collagen. The recombinant XII type collagen provided by the invention is easy to obtain, can realize efficient secretory expression, and meets the requirements of industrial production; the biological activity is good, and the proliferation and migration of human immortalized cartilage cells can be promoted.

The application discloses a flavonoid compound in eaglewood as well as a preparation method and application of the flavonoid compound, and relates to the technical field of medicines. The application extracts and separates a new compound from natural eaglewood, and the new compound is used in the preparation of anti-osteoporosis drugs. The compound is detected in vitro to obtain an induction effect of the compound on the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts, so as to affect the formation of osteoclasts. Meanwhile, the compound can promote the bone development of zebra fish through RT-qPCR detection, which indicates that the compound has anti-osteoporosis activity. The separation method of the compound is simple and easy to operate.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention provides application of polypeptide or related biological materials thereof in inhibition of osteoclast differentiation. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 or related biological materials thereof can remarkably inhibit osteoclast differentiation, further effectively treat and / or prevent osteoporosis and is suitable for preparing products for treating and / or preventing osteoporosis.

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.

The invention discloses a bionic bone marrow microenvironment assembly for hematopoietic stem cell in-vitro amplification and a preparation method. The bone marrow microenvironment assembly comprises a three-dimensional scaffold and osteoblasts (OBs), wherein the three-dimensional scaffold comprises chitosan (CS) and sodium alginate (Alg) which are prepared into mixed gel, and the mixed gel is freeze-dried to prepare the three-dimensional scaffold; wherein the osteoblasts (OBs) are obtained by culturing and induced differentiation of umbilical cord mesenchymal stem cells (MSCs) inoculated on a three-dimensional scaffold, and the osteoblasts (OBs) as stromal cells and the three-dimensional scaffold jointly form the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly; in the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly, the preparation of the three-dimensional scaffold comprises the processes of freezing, remelting, freezing, crosslinking, freeze-drying and the like, so that a three-dimensional space form with wrinkles on the pore surface and pore size distribution between 70 microns and 400 microns is generated in the three-dimensional scaffold, and the three-dimensional space form is closer to a real stem cell niche; therefore, the practical application effect of the bionic bone marrow microenvironment assembly for in-vitro amplification of the hematopoietic stem cells is further improved.

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The invention provides a composition for changing plasticity of bone meal particles as well as a preparation method and application of the composition, and relates to the technical field of biomedical materials. The composition is prepared from the following raw material components: bioactive glass, dihydrazide modified sodium hyaluronate, sodium hyaluronate with the molecular weight of 50kDa to 500kDa, a polylactic acid-glycolic acid copolymer and carboxymethyl cellulose. The preparation method of the dihydrazide modified sodium hyaluronate comprises the following steps: carrying out carboxyl activation on sodium hyaluronate, carrying out a cross-linking reaction on the activated hyaluronic acid and adipic dihydrazide, and then terminating the reaction. The composition provided by the invention not only can provide support, but also can adjust the degradation rate to be matched with the bone regeneration period, and all the components synergistically improve the mechanical property and the viscoelastic property. The composition disclosed by the invention can be formed in situ at a bone defect part, provides a space for growth and proliferation of bone cells, improves the biological activity and osteoinductivity of an artificial bone, and promotes bone growth and repair.

The invention discloses an application of polygonatum kingianum exosome in preparation of medicines for preventing and treating osteoporosis, the polygonatum kingianum exosome has good biocompatibility, can significantly inhibit osteoclast differentiation, promote osteocyte differentiation, effectively target bone tissues and significantly improve osteoporosis conditions, and has potential in preparation of medicines for preventing and treating osteoporosis. The polygonatum kingianum exosome is rich in source, has natural components with potential activity, is low in cost and is suitable for large-scale batch production.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

The invention provides application of linariin-6-O-glucoside in preparation of a product for preventing and treating osteoporosis, and relates to the field of biological medicine. According to the invention, dyeing experiments of alkaline phosphatase, alizarin red and tartaric acid resistant acid phosphatase prove that the sesaminin-6-O-glucoside has affinity for FPPS receptors, has the capability of promoting bone marrow mesenchymal stem cells to form bone cells, is superior to that of bisphosphate, and can inhibit the generation of osteoclasts; microCT (micro computed tomography) detection results show that the sesaminin-6-O-glucoside has the effect of relieving the osteoporosis and can promote the formation of bone trabecula. According to the application disclosed by the invention, it is proved for the first time that the sesaminin-6-O-glucoside has the effect of resisting osteoclast formation, and meanwhile, the sesaminin-6-O-glucoside also has a better osteogenesis effect, so that a basis is provided for developing the sesaminin-6-O-glucoside as a potential medicine for treating osteoporosis.

The application discloses a cell-penetrating peptide-oligonucleotide delivery system prepared based on a biological orthogonal click chemical reaction and a preparation method and application thereof. The cell-penetrating peptide with a cell membrane penetration function and the oligonucleotide with a biological function are connected through the biological orthogonal click chemical reaction, so that the biological activity of the biomolecule can be better maintained, a high fidelity is provided for a wide range of functional groups, no obvious toxic side effects are caused, and the oligonucleotide delivery is efficiently realized, thereby providing a new approach for preventing and treating osteoclast activation diseases.

The present invention provides methods of inhibiting osteoclastogenesis or inhibiting osteoclast activity using fused imidazole derivative compounds and pharmaceutical compositions. These methods may be used to treat various bone destructive disorders.

The application discloses a kind of polypeptide modified long afterglow nano-complex and its preparation method and application, nano-complex, for core-shell structure, core-shell structure is composed of the core body in inside and the shell that surrounds core body, core body is long afterglow nanomaterial, shell is by polypeptide modification and modified molecule modification, and drug loaded dendritic polymer;The nano-complex of the application can realize multiscale imaging to osteoclast, through in vivo afterglow imaging and in vivo two-photon microscopic imaging, the morphology, migration and distribution of osteoclast can be more accurately analyzed, avoid photo toxicity and background interference, improve imaging sensitivity;The nano-complex of the application is loaded with osteoporosis treatment drug alendronate ALN, and treatment drug can be replaced according to actual demand, and treatment scheme is adjusted, so that the drug loading system has universality.

The utility model discloses a kind of hollow intramedullary nail combined with pure magnesium physics, specifically including nail rod and splicing piece, nail rod is titanium alloy nail rod;Splicing piece includes the first release layer, second release layer, third release layer and fourth release layer set gradually, first release layer is magnesium alloy coating, second release layer is low-porosity pure magnesium layer, third release layer is high-porosity pure magnesium layer, fourth release layer is dense pure magnesium layer;Release groove is set on nail rod, release groove is connected with splicing piece, release groove is set in fracture end, for releasing magnesium ion.By being provided with splicing piece on titanium alloy nail rod, splicing piece releases magnesium ion of different concentration in different time period, magnesium ion can stimulate osteoblast differentiation and proliferation, accelerate bone tissue regeneration rate, while guaranteeing the mechanical structure intensity of intramedullary nail, realizes the acceleration fracture healing rate.

Embodiments of the disclosure include methods and compositions related to modulation of bone using particular fibroblasts. The modulation includes reducing osteoclast activity and / or activation and / or stimulating osteoblast activity. In particular cases, bone is modulated in an individual with a bone condition, such as osteoporosis. Particular fibroblasts may be delivered to reduce inflammatory cytokine production including RANK ligand.

The invention discloses a imperatorin and icariin composition and application thereof in preparation of medicines for treating osteoporosis, and belongs to the field of biological medicines. According to the invention, imperatorin and icariin in a mass ratio of 1: (1-5) are prepared into the pharmaceutical composition, and the pharmaceutical composition is applied to treatment of osteoporosis. Cell experiment and in-vivo experiment results show that the pharmaceutical composition provided by the invention has various pharmacological activities of regulating hormone and cell factor levels, resisting osteoclast absorption, promoting osteoblast generation and the like, and can also effectively increase the bone mineralization density of osteoporosis model mice. Based on natural traditional Chinese medicine active ingredients, the medicine which is efficient, low in toxicity and rich in pharmacological activity is provided for treatment of osteoporosis, and the medicine has outstanding clinical application value and wide application prospects.

The application discloses a 3D-printed intervertebral fusion cage, which is used to solve the problem of poor bone ingrowth effect of the prior art fusion cage, slow degradation speed, and early release of active ingredients, and the structure comprises a frame and an embedded pipe, the embedded pipe is arranged in the frame, the components are all made of degradable metal materials and can be gradually degraded in the human body, the embedded pipe is further encapsulated with active ingredients for promoting bone growth, and the active ingredients are released with the degradation of the embedded pipe, so that the early release of the drugs in the embedded pipe is avoided, long-acting effect is achieved, and of course a net beam is arranged in the gap of the frame, and the porous structure formed by the net beam further increases the bone ingrowth effect; the application creatively uses a 3D process to realize the encapsulation of the active ingredients and the forming of the porous support, and is combined with the degradable metal to realize the sustained release, so that a good growth condition is provided for the bone ingrowth in the porous support, the effect of the growth factors is fully played, and the treatment effect is improved.

The invention relates to an ROS-responsive macrophage-chondrocyte dual-targeting nano-micelle and a preparation method and application thereof, HA capable of targeting and highly expressing CD44 cells is taken as a carrier skeleton, chemical coupling with TK and CUR is carried out in sequence, self-assembly is carried out through intermolecular force to form a stable nano-micelle, and drugs JPH203 and KGN are entrapped at the same time, so that efficient loading and targeting delivery are realized. The HA can be specifically combined with RAW264.7 macrophages and articular cartilage cells for highly expressing a CD44 receptor in an inflammatory state, and is actively delivered in a targeting manner. The ROS response characteristic of TK is utilized, oxidative fracture is carried out in an OA high ROS microenvironment, and micelles are triggered to disintegrate and release drugs accurately. The released JPH203 can inhibit an inflammatory mTOR pathway and effectively resist inflammation, and KGN is beneficial to promoting cartilage cell proliferation and effectively collecting and promoting differentiation of mesenchymal stem cells into cartilage cells, so that in-situ cartilage regeneration is realized, and a more efficient solution with low side effects is provided for osteoarthritis treatment.